Pharmacokinetics of intravenous amikacin after rapid and slow infusion with special reference to hemodialysis

  • Jean -Claude Pechere
  • Robert Dugal
  • Marie -M. Pechere
Original Papers


The pharmacokinetics of amikacin, a recently introduced aminoglycoside structurally related to kanamycin, were determined in healthy volunteers after rapid and slow constant-rate intravenous administration of a 7.5 mg/kg dose. The elimination profile of amikacin can be described by two compartment open model kinetics. Peripheral distribution of the drug is extremely rapid, and β-phase concentrations decay with a half-life averaging about 2 hours, while inter-compartmental equilibrium is achieved in a little over 30 minutes. The volume of distribution averages about 25% of body weight. During hemodialysis, amikacin extraction from the blood reaches 97% ± 17% (mean ± 95% confidence interval) that of creatinine and 89% ± 20% that of blood urea nitrogen. A method of administration adapted to the kinetic properties of the antibiotic is proposed.


Amikacin pharmacokinetics two compartment open model analysis hemodialysis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. (1).
    Kawaguchi H. (1976): Discovery, chemistry and activity of amikacin, J. Infect. Dis.,134 (Suppl.): S242-S248.PubMedGoogle Scholar
  2. (2).
    Cooding P.G., Berman E., Lane A.Z. and Agre K. (1976): A review of results of clinical trials with amikacin, J. Infect. Dis.,134 (Suppl.): S441-S445Google Scholar
  3. (3).
    Cabana B.E. and Taggart J.G. (1973): Comparative pharmacokinetics of BB-K8 and kanamycin in dogs and humans, Antimicrob. Agents Chemother.,3, 478–483.PubMedGoogle Scholar
  4. (4).
    Kirby W.M.M., Clarke J.T., Libke R.D. and Regamey C. (1976): Clinical pharmacology of amikacin and kanamycin, J. Infect. Dis.,134 (Suppl.) : S312-S315.PubMedGoogle Scholar
  5. (5).
    Clarke J.T., Libke R.D., Regamey C. and Kirby W.M.M. (1976): Comparative pharmacokinetics of amikacin and kanamycin, Clin. Pharmacol. Ther.,15, 610–616.Google Scholar
  6. (6).
    Planner J., Forrey A.W., O’Neill M.A., Blair A.D., Christopher T.G. and Cutler R.E. (1976): Pharmacokinetics of amikacin in patients with normal or impaired renal function : radioenzymatic acetylation assay, J. Infect. Dis.,134 (Suppl.) : S323-S330.Google Scholar
  7. (7).
    Lode H., Grunert K., Koeppe P. and Langmeack H. (1976): Pharmacokinetic and clinical studies with amikacin, a new aminoglycoside antibiotic, J. Infect. Dis.,134 (Suppl.) : S316-S322.PubMedGoogle Scholar
  8. (8).
    Yates R.A., Mitchard M. and Wise R. (1978): Disposition studies with amikacin after rapid intravenous and intramuscular administration to human volunteers, J. Antimicrob. Chemother.,4, 335–341.CrossRefPubMedGoogle Scholar
  9. (9).
    Pijck J., Hallynck T., Soep H., Baert L., Daneels R. and Boelaert J. (1976): Pharmacokinetics of amikacin in patients with renal insufficiency : relationship of half-life and creatinine clearance, J. Infect. Dis.,134 (Suppl.): S331-S341.PubMedGoogle Scholar
  10. (10).
    Hoffler D., Koeppe P. and Demers H.G. (1976): Pharmacokinetics of amikacin for treatment of urinary tract infections in patients with reduced renal function. J. Infect. Dis.,134 (Suppl.): S369-S373.PubMedGoogle Scholar
  11. (11).
    McHenry M.C., Wagner J.G., Hall P.M., Vidt D.G. and Gavan T.L. (1976): Pharmacokinetics of amikacin in patients with impaired renal function, J. Infect. Dis.,134 (Suppl.) : S343-S348.PubMedGoogle Scholar
  12. (12).
    Levy J. and Klastersky J. (1975): Correlation of serum creatinine concentration and amikacin half-life, J. Clin. Pharmacol.,15, 505–705.Google Scholar
  13. (13).
    Regeur L., Colding H., Jensen H. and Kampmann J.P. (1977): Pharmacokinetics of amikacin during hemodialysis and peritoneal dialysis, Antimicrob. Agents Chemother.,11, 214–218.PubMedGoogle Scholar
  14. (14).
    Danish M., Schultz R. and Jusko W. (1974): Pharmacokinetics of gentamicin and kanamycin during hemodialysis, Antimicrob. Agents Chemother.,6, 841–847.PubMedGoogle Scholar
  15. (15).
    Madhavan T., Yaremchuk K., Levin N., Pohlod D., Burch K., Fisher F., Cox F. and Quinn E.L. (1976): Effect of renal failure and dialysis on the serum concentration of the aminoglycoside amikacin, Antimicrob. Agents Chemother.,10, 464–466.PubMedGoogle Scholar
  16. (16).
    Bennett J.V., Brodie J.L., Benner E.J. and Kirby W.M.M. (1966): Simplified accurate method for antibiotic assay in clinical specimens, App. Microbiol.,14, 170–177.Google Scholar
  17. (17).
    Sedman A.J. and Wagner J.G. (1976): CSTRIP, a Fortran IV computer program for obtaining initial polyex potential parameter estimates, J. Pharm. Sci.,65, 1006–1010.CrossRefPubMedGoogle Scholar
  18. (18).
    Metzler C.M. (1976): NONLIN, a computer program for parameter estimation in non-linear situations. Technical report #7292/69/7292/005, Pharmaceutical Research and Development Division, The Upjohn Company, Kalamazoo, Michigan.Google Scholar
  19. (19).
    Riegelman S., Loo J.C.K. and Rowland M. (1968): Shortcomings in pharmacokinetics analysis by conceiving the body to exhibit properties of a single compartment, J. Pharm. Sci.,57, 117–123.CrossRefPubMedGoogle Scholar
  20. (20).
    Loo J.C.K. and Riegelman S. (1970): Assessment of pharmacokinetic constants from post-infusion blood curve obtained after I.V. infusion, J. Pharm. Sci.,59, 53–55.CrossRefPubMedGoogle Scholar
  21. (21).
    Wagner J.G. (1974): A safe method for rapidly achieving plasma concentration plateaus, Clin. Pharmacol. Ther.,16, 691–700.PubMedGoogle Scholar
  22. (22).
    Péchère J.C., Roy B. and Dugal R. (1976): Distribution and elimination kinetics of intravenously and intramuscularly administered tobramycin in man, Int. J. Clin. Pharmacol.,74, 313–318.Google Scholar
  23. (23).
    Péchère J.C., Péchère M.M. and Dugal R. (1976): Clinical pharmacokinetics of sisomicin : two compartment model analysis of serum data after I.V. and I.M. administration, Europ. J. Clin. Pharmacol.,10, 251–256.CrossRefGoogle Scholar
  24. (24).
    Péchère J.C., Dugal R. and Péchère M.M. (1978): Kinetics of netilmicin in man, Clin. Pharmacol. Ther.,23, 677–684.PubMedGoogle Scholar
  25. (25).
    Black R.E., Law W.K., Weinstein R.J., Young L.S. and Hewitt W.L. (1976): Ototoxicity of amikacin, Antimicrob. Agents Chemother.,9, 956–961.Google Scholar
  26. (26).
    Schentag J.J. and Jusko W.J. (1977): Renal clearance and tissue accumulation of gentamicin, Clin. Pharmacol. Ther.,22, 364–370.PubMedGoogle Scholar
  27. (27).
    Péchère J.C. and Dugal R. (1976): Pharmacokinetics of intravenously administered tobramycin in normal volunteers and in renal-impaired and hemodialyzed patients, J. Inf. Dis.,134 (Suppl.): S118-S124.Google Scholar
  28. (28).
    Péchère J.C., Péchère M.M. and Dugal R. (1976): Clinical pharmacokinetics of sisomicin : dosage schedules in renal-impaired patients. Antimicrob. Agents Chemother.,9, 761–765.PubMedGoogle Scholar
  29. (29).
    Péchère J.C., Dugal R. and Péchère M.M. (1978): Clinical pharmacokinetics of netilmicin in renal insufficiency and hemodialysis, Clin. Pharmacokin.,3, 395–406.CrossRefGoogle Scholar
  30. (30).
    Valdivieso M., Feld R., Rodriguez V. and Bodey G.P. (1975): Amikacin therapy in infections in neutropenic patients, Am. J. Med. Sci.,270, 453–463.CrossRefPubMedGoogle Scholar
  31. (31).
    Feld R., Valdivieso M., Bodey G.P. and Rodriguez V. (1977): A comparative trial sisomicin therapy by intermittent versus continuous infusion, Am. J. Med. Sci.,274, 179–188.CrossRefPubMedGoogle Scholar
  32. (32).
    Bodey G.P., Chang H.-Y., Rodriguez V. and Stewart D. (1975): Feasibility of administering aminoglycoside antibiotics by continuous intravenous infusion, Antimicrob. Agents Chemother.,8, 328–333.Google Scholar

Copyright information

© Springer-Verlag 1979

Authors and Affiliations

  • Jean -Claude Pechere
    • 1
  • Robert Dugal
    • 2
  • Marie -M. Pechere
    • 1
  1. 1.Department of Microbiology, School of MedicineLaval UniversityQuebec CityCanada
  2. 2.Institut National de la Recherche Scientifique (Santé)MontrealCanada

Personalised recommendations